Antimicrobial peptides of an anti-lipopolysaccharide factor, epinecidin-1, and hepcidin reduce the lethality of Riemerella anatipestifer sepsis in ducks

Pan, Chieh-Yu; Chow, The-Yuan; Yu, Chao-Yuan; Yu, Chang-You; Chen, Jian-Chyi; Chen, Jyh-Yih

doi:10.1016/j.peptides.2010.01.013

Cited by 26 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epinecidin-1 treatment resulted in 100% clearance of P. aeruginosa ATCC 19660 and P. aeruginosa R bacteria from blood after 48 h. Moreover, the numbers of CFU of the ATCC 19660 and R strains decreased in the peritoneum, spleen, liver, and mesenteric lymph nodes after 48 h of epinecidin-1 treatment. Epinecidin-1 treatment was also previously reported to reduce the bacterial (Riemerella anatipestifer) load in duck (41). Taken together, these findings highlight the utility of epinecidin-1 in treating P. aeruginosa-infected mice.…”

Section: Discussionsupporting

confidence: 62%

Epinecidin-1 Has Immunomodulatory Effects, Facilitating Its Therapeutic Use in a Mouse Model of Pseudomonas aeruginosa Sepsis

Pan

Chen

Sheen

et al. 2014

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

e Antimicrobial peptides (AMPs) are garnering attention as possible alternatives to antibiotics. Here, we describe the antimicrobial properties of epinecidin-1 against a multidrug-resistant clinical isolate of P. aeruginosa (P. aeruginosa R) and a P. aeruginosa strain from ATCC (P. aeruginosa ATCC 19660) in vivo. The MICs of epinecidin-1 against P. aeruginosa R and P. aeruginosa ATCC 19660 were determined and compared with those of imipenem. Epinecidin-1 was found to be highly effective at combating peritonitis infection caused by P. aeruginosa R or P. aeruginosa ATCC 19660 in mouse models, without inducing adverse behavioral effects or liver or kidney toxicity. Taken together, our results indicate that epinecidin-1 enhances the rate of survival of mice infected with the bacterial pathogen P. aeruginosa through both antimicrobial and immunomodulatory effects.

show abstract

Section: Discussionsupporting

confidence: 62%

Epinecidin-1 Has Immunomodulatory Effects, Facilitating Its Therapeutic Use in a Mouse Model of Pseudomonas aeruginosa Sepsis

Pan

Chen

Sheen

et al. 2014

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…Septic shock was induced by intraperitoneal administration of V . vulnificus using experimental methods that have been described in several animal models [29,30]. The percent survival after injection of only TP3 at 20, 30, 40, 50 μg/fish was 86.7%, 73.3%, 66.7%, and 56.7%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Study of the Antimicrobial Activity of Tilapia Piscidin 3 (TP3) and TP4 and Their Effects on Immune Functions in Hybrid Tilapia (Oreochromis spp.)

Pan

Tsai

et al. 2017

PLoS ONE

Self Cite

View full text Add to dashboard Cite

To address the growing concern over antibiotic-resistant microbial infections in aquatic animals, we tested several promising alternative agents that have emerged as new drug candidates. Specifically, the tilapia piscidins are a group of peptides that possess antimicrobial, wound-healing, and antitumor functions. In this study, we focused on tilapia piscidin 3 (TP3) and TP4, which are peptides derived from Oreochromis niloticus, and investigated their inhibition of acute bacterial infections by infecting hybrid tilapia (Oreochromis spp.) with Vibrio vulnificus and evaluating the protective effects of pre-treating, co-treating, and post-treating fish with TP3 and TP4. In vivo experiments showed that co-treatment with V. vulnificus and TP3 (20 μg/fish) or TP4 (20 μg/fish) achieved 95.3% and 88.9% survival rates, respectively, after seven days. When we co-injected TP3 or TP4 and V. vulnificus into tilapia and then re-challenged the fish with V. vulnificus after 28 days, the tilapia exhibited survival rates of 35.6% and 42.2%, respectively. Pre-treatment with TP3 (30 μg/fish) or TP4 (20 μg/fish) for 30 minutes prior to V. vulnificus infection resulted in high survival rates of 28.9% and 37.8%, respectively, while post-treatment with TP3 (20 μg/fish or 30 μg/fish) or TP4 (20 μg/fish) 30 minutes after V. vulnificus infection yielded high survival rates of 33.3% and 48.9%. In summary, pre-treating, co-treating, and post-treating fish with TP3 or TP4 all effectively decreased the number of V. vulnificus bacteria and promoted significantly lower mortality rates in tilapia. The minimum inhibitory concentrations (MICs) of TP3 and TP4 that were effective for treating fish infected with V. vulnificus were 7.8 and 62.5 μg/ml, respectively, whereas the MICs of kanamycin and ampicillin were 31.2 and 3.91 μg/ml. The antimicrobial activity of these peptides was confirmed by transmission electron microscopy (TEM) and scanning electron microscopy (SEM), both of which showed that V. vulnificus disrupted the outer membranes of cells, resulting in the loss of cell shape and integrity. We examined whether TP3 and TP4 increased the membrane permeability of V. vulnificus by measuring the fluorescence resulting from the uptake of 1-N-phenyl-naphthylamine (NPN). Treating fish with TP3 and TP4 under different pH and temperature conditions did not significantly increase MIC values, suggesting that temperature and the acid-base environment do not affect AMP function. In addition, the qPCR results showed that TP3 and TP4 influence the expression of immune-responsive genes, including interleukin (IL)-1β, IL-6, and IL-8. In this study, we demonstrate that TP3 and TP4 show potential for development as drugs to combat fish bacterial infections in aquaculture.

show abstract

“…There are many antimicrobial functions reported for fish AMPs [23]. Almost all fish AMPs show direct antibacterial functions and form pores in bacterial membranes [24]. On the other hand, AMPs have immunomodulatory functions, such as defensin against viral hemorrhagic septicemia virus by modulating proinflammatory cytokines [25].…”

Section: Discussionmentioning

confidence: 99%

“…The mechanism of the antibacterial action of epinecidin-1 has not been fully explored, but it involves direct destruction of bacterial walls [24]. Such an interaction of a bacteria-killing mechanism may exist that induces strong immunostimulatory activity that can bring about life-threatening inflammatory disorders by bacterial wall molecules.…”

Section: Discussionmentioning

confidence: 99%

Insights into the antibacterial and immunomodulatory functions of the antimicrobial peptide, epinecidin-1, against Vibrio vulnificus infection in zebrafish

Pan

Hui

et al. 2011

Fish & Shellfish Immunology

Self Cite

View full text Add to dashboard Cite

Antimicrobial peptides of an anti-lipopolysaccharide factor, epinecidin-1, and hepcidin reduce the lethality of Riemerella anatipestifer sepsis in ducks

Cited by 26 publications

References 38 publications

Epinecidin-1 Has Immunomodulatory Effects, Facilitating Its Therapeutic Use in a Mouse Model of Pseudomonas aeruginosa Sepsis

Epinecidin-1 Has Immunomodulatory Effects, Facilitating Its Therapeutic Use in a Mouse Model of Pseudomonas aeruginosa Sepsis

Study of the Antimicrobial Activity of Tilapia Piscidin 3 (TP3) and TP4 and Their Effects on Immune Functions in Hybrid Tilapia (Oreochromis spp.)

Insights into the antibacterial and immunomodulatory functions of the antimicrobial peptide, epinecidin-1, against Vibrio vulnificus infection in zebrafish

Contact Info

Product

Resources

About